Verastem, Inc.
VSTM
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 20ā¦ read more
Healthcare
Biotechnology
14 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$6.89
Price+1.03%
$0.07
1Y
Price
Market Cap
$605.449m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-192.4%
EBITDA Margin-196.0%
Net Profit Margin-279.1%
Free Cash Flow Margin-192.4%
EBITDA Margin-196.0%
Net Profit Margin-279.1%
Free Cash Flow MarginRevenue
$49.585m
+60.4%
1y CAGR+89.9%
3y CAGR+42.4%
5y CAGREarnings
-$193.959m
+7.4%
1y CAGR-34.2%
3y CAGR-30.2%
5y CAGREPS
-$2.73
+9.6%
1y CAGR+11.6%
3y CAGR+12.0%
5y CAGRBook Value
$81.777m
$227.808m
Assets$146.031m
Liabilities$85.475m
DebtDebt to Assets
37.5%
-0.4x
Debt to EBITDAFree Cash Flow
-$152.294m
-10.7%
1y CAGR-21.1%
3y CAGR-24.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company